Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma

Neeraj Agarwal, MD
Published Online: Tuesday, Nov 14, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Several new treatment combinations are being tested with checkpoint inhibitors, IDO1 inhibitors, tyrosine kinase inhibitors (TKIs), and VEGFR TKIs, explains Agarwal.

The way patients with newly diagnosed metastatic renal cell carcinoma are treated will be completely different in the next few years, says Agarwal.


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Several new treatment combinations are being tested with checkpoint inhibitors, IDO1 inhibitors, tyrosine kinase inhibitors (TKIs), and VEGFR TKIs, explains Agarwal.

The way patients with newly diagnosed metastatic renal cell carcinoma are treated will be completely different in the next few years, says Agarwal.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x